Showing posts with label endocrinology. Show all posts
Showing posts with label endocrinology. Show all posts

Tuesday, 2 July 2019

[Endocrinology] Introduction

This field specialises in diseases of the endocrine system.

 

Etymology

Ancient Greek ἔνδον (éndon) = inner; internal

Ancient Greek κρίνω (krínō) = to separate
In endocrine, crine (krínō) means "to secrete."

Ancient Greek λογία (logia) = study

Endocrinology = the study of internal secretions.

 

Subspecialties

  • Paediatric endocrinology

 

History taking

 

Physical examination

  • Examination of suspected thyroid disease
  • Examination of diabetic patients

 

Common problems:

     

    Endocrine system diseases

     

    Diseases:

        Thursday, 13 June 2019

        Myxoedema

        Disease class: Hypothyroidism

        Consequences

        • Psychosis - "myxoedema madness"
        • Coma

        Developmental bone diseases

        Disease class: Bone diseases

        Types

        Ambiguous genitalia

        Noonan syndrome


        Features

        Failure to thrive
        Congenital heart defects
        Bleeding disorders
        Usually normal intelligence

         

        Genetics

        Caused by a mutation in one of several genes
        Usually autosomal dominant inheritance

         

        Pathophysiology

        In 70% of cases, the affected genes play a role in the Ras/mitogen activated protein kinase signaling pathways.

         

        Complications

        Leukaemia

         

        Management

        Growth hormone may help children to reach 

        Thursday, 18 April 2019

        Hyponatraemia


        This refers to sodium (natrium) levels in the blood below the reference range.

         

        Management

        Beware: rapid reversal of hyponatraemia with aggressive treatment can cause a severe disease: central pontine myelinolysis. Sodium restoration must be very slow and gradual. Specialist advice should be sought.


        See also

        Hypokalaemia


        This refers to potassium (kalium) levels in the blood below the reference range.

         

        Management

         

        See also

        Hypocalcaemia


        This refers to calcium levels in the blood below the reference range.

         

        Aetiology / Causes

        Low PTH (hypoparathyroidism)

        • Genetic disorders
          • Abnormal parathyroid gland development
          • Abnormal PTH synthesis
          • Activating mutations of calcium-sensing receptor (autosomal dominant hypocalcaemia or sporadic isolated hypoparathyroidism)
        • Postsurgical
          • Thyroidectomy
          • Parathyroidectomy
          • Radical neck dissection
        • Autoimmune
          • Autoimmune polyglandular syndrome (associated with chronic mucocutaneous candidiasis and primary adrenal insufficiency)
          • Isolated hypoparathyroidism due to activating antibodies to calcium-sensing receptor
        • Infiltration of the parathyroid gland (granulomatous, iron overload, metastases)
        • Radiation-induced destruction parathyroid glands
        • Hungry bone syndrome (post-parathyroidectomy)
        • HIV infection

        High PTH (secondary hyperparathyroidism in response to hypocalcaemia)

        Drugs

        • Inhibitors of bone resorption (bisphosphonates, calcitonin, denosumab), especially in vitamin D deficiency
        • Cinacalcet
        • Calcium chelators (EDTA, citrate, phosphate)
        • Foscarnet (due to intravascular complexing with calcium)
        • Phenytoin (due to conversion of vitamin D to inactive metabolites)
        • Fluoride poisoning

        Disorders of magnesium metabolism

        • Hypomagnesaemia can reduce PTH secretion or cause PTH resistance and is therefore associated with normal, low, or high PTH levels.

         

        Management

         

         See also

        Hypercalcaemia

        Definition

        • This refers to calcium levels in the blood above the reference range.

         

        Causes

         

        Management

        Diagram created by uptodate.com

        Investigations

        1. Serum calcium
        2. Total corrected calcium
        3. Intact parathyroid hormone (PTH)
        4. PTHrP
        5. Chest radiograph
        6. CT-thorax scan
        7. 1,25-dihydroxyvitamin D
        8. Lymph node biopsy
        9. 25-hydroxyvitamin D
        10. SPEP
        11. UPEP
        12. Serum free light chain assay

         

        See also

        Hypernatraemia


        This refers to sodium (natrium) levels in the blood above the reference range. 

         

        Management

         

        See also

        Hyperkalaemia


        This refers to potassium (kalium) levels in the blood above the reference range.

         

        Management

        Tuesday, 9 April 2019

        Aldosterone antagonists

        Also known as

        • Mineralocorticoid antagonists
        • MRAs, MRCAs

         

        Key examples

        • Spironolactone
        • Eplerenone

         

        Common indications

        1. Ascites and oedema due to liver cirrhosis: spironolactone is the first-line diuretic.
        2. Chronic heart failure: of at least moderate severity or arising within 1 month of a myocardial infarction, usually as an addition to a β-blocker and an ACE inhibitor/angiotensin receptor blocker.
        3. Primary hyperaldosteronism: for patients awaiting surgery or for whom surgery is not an option.

         

        Mechanisms of action

        • Aldosterone is a mineralocorticoid that is produced in the adrenal cortex. It acts on mineralocorticoid receptors in the distal tubules of the kidney to increase the activity of luminal epithelial sodium channels (ENaC). This increases the reabsorption of sodium and water (which elevates blood pressure) with the by-product of increased potassium excretion.
        • Aldosterone antagonists inhibit the effect of aldosterone by competitively binding to the aldosterone receptor. This increases sodium and water excretion and potassium retention. Their effect is greatest in primary hyperaldosteronism or when circulating aldosterone is increased, e.g. in cirrhosis.

         

        Important adverse effects

        • An important adverse effect of aldosterone antagonists is hyperkalaemia, which can lead to muscle weakness, arrhythmias and even cardiac arrest. 
        • Spironolactone causes gynaecomastia, which can have a significant impact on patient adherence. 
        • Aldosterone antagonists can cause liver impairment and jaundice and are a cause of Stevens–Johnson syndrome (a T cell-mediated hypersensitivity reaction) that causes a bullous skin eruption.

         

        Warnings

        • Aldosterone antagonists are contraindicated in patients with severe renal impairment, hyperkalaemia and Addison’s disease (who are aldosterone deficient). 
        • Aldosterone antagonists can cross the placenta during pregnancy and appear in breast milk so should be avoided where possible in pregnant or lactating women.

         

        Important interactions

        • The combination of an aldosterone antagonist with other potassium-elevating drugs, including ACE inhibitors and angiotensin receptor blockers, increases the risk of hyperkalaemia. 
        • Nevertheless, when supported by appropriate monitoring, this may be a beneficial combination in the context of heart failure. 
        • Aldosterone antagonists should not be combined with potassium supplements except in specialist practice.